Top

Published in:

01-01-2011

Neuroimaging in Psychiatric Disorders

Author: Joseph C. Masdeu, M.D., Ph. D.

Published in: Neurotherapeutics | Issue 1/2011

Summary

In psychiatry, neuroimaging facilitates the diagnosis of psychiatric disorders and the development of new medications. It is used to detect structural lesions causing psychosis and to differentiate depression from neurodegenerative disorders or brain tumors. Functional neuroimaging, mostly in the form of molecular neuroimaging with positron emission tomography or single photon emission tomography, facilitates the identification of therapeutic targets, the determination of the dose of a new drug needed to occupy its target in the brain, and the selection of patients for clinical trials.

Available only for authorised users

Agarwal N, Port JD, Bazzocchi M, Renshaw PF. Update on the use of MR for assessment and diagnosis of psychiatric diseases. Radiology 2010;255:23–41.CrossRefPubMed

Inkster B, Nichols TE, Saemann PG, et al. Pathway-based approaches to imaging genetics association studies: Wnt signaling, GSK3beta substrates and major depression. Neuroimage 2010;53:908–917.CrossRefPubMed

Bunevicius A, Deltuva VP, Deltuviene D, Tamasauskas A, Bunevicius R. Brain lesions manifesting as psychiatric disorders: eight cases. CNS Spectr 2008;13:950–958.PubMed

Sherwin I, Peron-Magnan P, Bancaud J, Bonis A, Talairach J. Prevalence of psychosis in epilepsy as a function of the laterality of the epileptogenic lesion. Arch Neurol 1982;39:621–625.PubMed

Boone KB, Miller BL, Rosenberg L, Durazo A, McIntyre H, Weil M. Neuropsychological and behavioral abnormalities in an adolescent with frontal lobe seizures. Neurology 1988;38:583–586.PubMed

Moise D, Madhusoodanan S. Psychiatric symptoms associated with brain tumors: a clinical enigma. CNS Spectr 2006;11:28–31.PubMed

Albert DJ, Walsh ML, Jonik RH. Aggression in humans: what is its biological foundation? Neurosci Biobehav Rev 1993;17:405–425.CrossRefPubMed

Grafman J, Vance SC, Weingartner H, Salazar AM, Amin D. The effects of lateralized frontal lesions on mood regulation. Brain 1986;109:1127–1148.CrossRefPubMed

Masdeu JC, Zubieta JL, Arbizu J. Neuroimaging as a marker of the onset and progression of Alzheimer's disease. J Neurol Sci 2005;236:55–64.CrossRefPubMed

10.

Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718–1725.CrossRefPubMed

11.

Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007;130:2616–2635.CrossRefPubMed

12.

Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007;69:871–877.CrossRefPubMed

13.

Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001;286:2120–2127.CrossRefPubMed

14.

Jagust W, Thisted R, Devous MD, Sr., et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical–pathologic study. Neurology 2001;56:950–956.PubMed

15.

Lowe VJ, Kemp BJ, Jack CR, Jr., et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009;50:878–886.CrossRefPubMed

16.

Reisch T, Brekenfeld C, Barth A. A case of hydrocephalus occlusus presenting as bipolar disorder. Acta Psychiatr Scand 2005;112:159–162; discussion 162–153.CrossRefPubMed

17.

McMurtray AM, Chen AK, Shapira JS, et al. Variations in regional SPECT hypoperfusion and clinical features in frontotemporal dementia. Neurology 2006;66:517–522.CrossRefPubMed

18.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). Arlington, Va: American Psychiatric Association; 2000.

19.

Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 2009;34:74–89.CrossRefPubMed

20.

Sun D, van Erp TG, Thompson PM, et al. Elucidating a magnetic resonance imaging-based neuroanatomic biomarker for psychosis: classification analysis using probabilistic brain atlas and machine learning algorithms. Biol Psychiatry 2009;66:1055–1060.CrossRefPubMed

21.

Meisenzahl EM, Koutsouleris N, Bottlender R, et al. Structural brain alterations at different stages of schizophrenia: a voxel-based morphometric study. Schizophr Res 2008;104:44–60.CrossRefPubMed

22.

Thompson PM, Bartzokis G, Hayashi KM, et al. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb Cortex 2009;19:1107–1123.CrossRefPubMed

23.

Eisenberg DP, Sarpal D, Kohn PD, et al. Catechol-o-methyltransferase valine(158)methionine genotype and resting regional cerebral blood flow in medication-free patients with schizophrenia. Biol Psychiatry 2010;67:287–290.CrossRefPubMed

24.

Blasi G, Taurisano P, Papazacharias A, et al. Nonlinear response of the anterior cingulate and prefrontal cortex in schizophrenia as a function of variable attentional control. Cereb Cortex 2010;20:837–845.CrossRefPubMed

25.

Meyer-Lindenberg AS, Olsen RK, Kohn PD, et al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry 2005;62:379–386.CrossRefPubMed

26.

Benetti S, Mechelli A, Picchioni M, Broome M, Williams S, McGuire P. Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state. Brain 2009;132:2426–2436.CrossRefPubMed

27.

Whitfield-Gabrieli S, Thermenos HW, Milanovic S, et al. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci USA 2009;106:1279–1284.CrossRefPubMed

28.

Savitz JB, Drevets WC. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience 2009;164:300–330.CrossRefPubMed

29.

Gron G, Bittner D, Schmitz B, Wunderlich AP, Riepe MW. Subjective memory complaints: objective neural markers in patients with Alzheimer's disease and major depressive disorder. Ann Neurol 2002;51:491–498.CrossRefPubMed

30.

Wong DF, Tauscher J, Grunder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009;34:187–203.CrossRefPubMed

31.

Passchier J, Gentile G, Porter R, et al. Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography. Synapse 2010;64:542–549.CrossRefPubMed

32.

Murthy N, Passchier J, Gunn RN, et al. [¹¹C]GSK931145: A new PET ligand for glycine transporter 1. Neuro-Receptor Meeting. Pittsburgh 2008.

33.

Lesko LJ, Atkinson AJ, Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001;41:347–366.CrossRefPubMed

34.

Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514–520.CrossRefPubMed

35.

Grunder G, Landvogt C, Vernaleken I, et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 2006;31:1027–1035.CrossRefPubMed

36.

Kessler RM, Ansari MS, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006;31:1991–2001.CrossRefPubMed

37.

Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002;5:267–271.CrossRefPubMed

38.

Slifstein M, Kolachana B, Simpson EH, et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [(11)C]NNC112 and PET. Mol Psychiatry 2008;13:821–827.CrossRefPubMed

39.

Catafau AM, Suarez M, Bullich S, et al. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. Neuroimage 2009;46:447–458.CrossRefPubMed

40.

Kessler RM, Woodward ND, Riccardi P, et al. Dopamine D(2) receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 2009;65:1024–1031.CrossRefPubMed

41.

Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D(2) receptors by aripiprazole in schizophrenia with PET and [(18)F]Fallypride. Neuropsychopharmacology 2008;33:3111–3125.

42.

Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004;19:1175–1182.CrossRefPubMed

43.

Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000;97:8104–8109.CrossRefPubMed

44.

Abi-Dargham A, Giessen EV, Slifstein M, Kegeles LS, Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 2009;65:1091–1093.CrossRefPubMed

45.

Woodward ND, Zald DH, Ding Z, et al. Cerebral morphology and dopamine D2/D3 receptor distribution in humans: a combined [18F]fallypride and voxel-based morphometry study. Neuroimage 2009;46:31–38.CrossRefPubMed

46.

Buchsbaum MS, Christian BT, Lehrer DS, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 2006;85:232–244.CrossRefPubMed

47.

Catafau AM, Perez V, Plaza P, et al. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. Psychopharmacology (Berl) 2006;189:145–153.CrossRef

48.

Pissarek MB, Oros-Peusquens AM, Schramm NU. Challenge by the murine brain: multi-pinhole SPECT of 123I-labelled pharmaceuticals. J Neurosci Methods 2008;168:282–292.CrossRefPubMed

49.

Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002;27:248–259.CrossRefPubMed

50.

Suhara T, Takano A, Sudo Y, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 2003;60:386–391.CrossRefPubMed

51.

Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004;37:243–265.CrossRefPubMed

52.

Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006;59:216–223.CrossRefPubMed

53.

Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 2006;59:816–820.CrossRefPubMed

54.

Yoon SJ, Lyoo IK, Haws C, Kim TS, Cohen BM, Renshaw PF. Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2009;34:1810–1818.CrossRefPubMed

55.

Kozel FA, Johnson KA, Nahas Z, et al. Fractional anisotropy changes after several weeks of daily left high-frequency repetitive transcranial magnetic stimulation of the prefrontal cortex to treat major depression. J ECT 2010 Oct 1. [Epub ahead of print].

56.

Coenen VA, Honey CR, Hurwitz T, et al. Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson's disease. Neurosurgery 2009;64:1106–1114; discussion 1114-1105.CrossRefPubMed

57.

Masdeu J. Neuroimaging of disorders leading to dementia. Continuum (AAN) 2008;14:144–163.

Title: Neuroimaging in Psychiatric Disorders
Author: Joseph C. Masdeu, M.D., Ph. D.
Publication date: 01-01-2011
Publisher: Springer-Verlag
Published in: Neurotherapeutics / Issue 1/2011
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI: https://doi.org/10.1007/s13311-010-0006-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Neuroimaging in Psychiatric Disorders

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 1/2011

Neuroimaging in Dementia

Fourth Annual Huntington Disease Clinical Research Symposium

Update in Neuroimaging

The Role of Medical Imaging in Defining CNS Abnormalities Associated with HIV-Infection and Opportunistic Infections

Imaging for the Diagnosis and Management of Traumatic Brain Injury

MRI in Rodent Models of Brain Disorders